C4 Therapeutics, Inc. (CCCC)

NASDAQ: CCCC · IEX Real-Time Price · USD
7.07
-0.08 (-1.12%)
Jun 29, 2022 11:46 AM EDT - Market open
-1.12%
Market Cap 345.00M
Revenue (ttm) 46.01M
Net Income (ttm) -94.54M
Shares Out 48.80M
EPS (ttm) -1.99
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 73,883
Open 7.09
Previous Close 7.15
Day's Range 6.77 - 7.12
52-Week Range 4.84 - 51.21
Beta n/a
Analysts Buy
Price Target 30.23 (+327.6%)
Earnings Date Aug 10, 2022

About CCCC

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrade... [Read more...]

Industry Biotechnology
IPO Date Oct 2, 2020
Employees 121
Stock Exchange NASDAQ
Ticker Symbol CCCC
Full Company Profile

Financial Performance

In 2021, CCCC's revenue was $45.79 million, an increase of 37.93% compared to the previous year's $33.20 million. Losses were -$83.89 million, 26.5% more than in 2020.

Financial Statements

Analyst Forecast

According to 18 analysts, the average rating for CCCC stock is "Buy." The 12-month stock price forecast is 30.23, which is an increase of 327.58% from the latest price.

Price Target
$30.23
(327.58% upside)
Analyst Consensus: Buy
Stock Forecasts

News

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable ...

WATERTOWN, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to d...

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates

C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of -6.56% and 0.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

– Data from Ongoing CFT7455 Phase 1/2 Trial Presented at the American Association for Cancer Research (AACR) Annual Meeting; Enrollment Continues in Cohorts B1 and C –

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of C4 Therapeutics, Inc. - CCCC

New York, New York--(Newsfile Corp. - April 21, 2022) - Pomerantz LLP is investigating claims on behalf of investors of C4 Therapeutics, Inc. ("C4" or the "Company") (NASDAQ: CCCC). Such investors are a...

Why C4 Therapeutics Stock Is Plunging Today

C4 Therapeutics Inc (NASDAQ: CCCC) shares are trading significantly lower Friday afternoon after the company presented data from Cohort A of its ongoing Phase 1/2 clinical trial of CFT7455. Cohort A, th...

C4 Therapeutics Stock Falls On CFT7455 Dose Limiting Toxicity In Multiple Myeloma Trial

C4 Therapeutics Inc (NASDAQ: CCCC) has presented data from Cohort A of its ongoing Phase 1/2 trial of CFT7455 for multiple myeloma (MM) and non-Hodgkin's lymphomas (NHL).  The data will be presented at ...

C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF...

– Single Agent CFT7455 Induces Deep and Durable Degradation of IKZF1/3 and Meaningful Decreases in Serum Free Light Chain at Doses Lower than Expected Based on Pre-clinical Studies –

C4 Therapeutics Appoints Utpal Koppikar to Board of Directors

– Utpal Koppikar, Veteran Life Sciences Industry Financial Executive, Appointed as Independent Member of the Board of Directors, Chair of Audit Committee and Member of Organization, Leadership and Compe...

C4 Therapeutics Announces FDA Orphan Drug Designation for CFT8634 for the Treatment of Soft Tissue Sarcoma

WATERTOWN, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to...

C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022

- Clinical Data from Cohort A of the Ongoing Phase 1/2 Trial of CFT7455, a Novel IKZF1/3 Degrader, Accepted as Late-Breaker Poster Presentation –

C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights

– Data from Cohort A of the Ongoing Phase 1/2 Trial of CFT7455, a Novel IKZF1/3 Degrader, Accepted for Presentation at the American Association for Cancer Research (AACR)  Annual Meeting –

C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation Portfolio

– Initial Phase 1 Data for CFT7455, a Novel IKZF1/3 Degrader, Expected in 1H 2022–

C4 Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

WATERTOWN, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selecti...

What Makes C4 Therapeutics, Inc. (CCCC) a New Buy Stock

C4 Therapeutics, Inc. (CCCC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

C4 Therapeutics Added to NASDAQ Biotechnology Index

WATERTOWN, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selecti...

C4 Therapeutics (CCCC) Sees Hammer Chart Pattern: Time to Buy?

C4 Therapeutics (CCCC) has been struggling lately, but the selling pressure may be coming to an end soon.

C4 Therapeutics, Inc. (CCCC) Moves to Buy: Rationale Behind the Upgrade

C4 Therapeutics, Inc. (CCCC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results

– Phase 1/2 study of CFT7455, a Novel IKZF1/3 Degrader, Progressing with Data Expected in 2022; Trial-in-Progress Poster Accepted for Presentation at 63 rd ASH Annual Meeting –

Why C4 Therapeutics (CCCC) Might Surprise This Earnings Season

C4 Therapeutics (CCCC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

C4 Therapeutics Multiple Myeloma Candidate Scores FDA Orphan Drug Tag

The FDA has granted Orphan Drug Designation to C4 Therapeutics Inc (NASDAQ: CCCC) CFT7455 for multiple myeloma. CFT7455 is an orally bioavailable MonoDAC degrader targeting IKZF1/3.

C4 Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results

– Dosed First Patient in Phase 1/2 Clinical Trial of CFT7455, a novel IKZF1/3 Degrader, in Hematologic Malignancies; Data Expected in 2022 –

C4 Therapeutics Announces FDA Orphan Drug Designation for CFT7455 for the Treatment of Multiple Myeloma

WATERTOWN, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selecti...

C4 Therapeutics Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Add...

WATERTOWN, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selecti...

C4 Therapeutics Announces Pricing of Public Offering

WATERTOWN, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selecti...

C4 Therapeutics Launches Proposed Public Offering

WATERTOWN, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selecti...